Nimorazole

Generic Name: Nimorazole

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₉H_₁₄N_₄O_₃

CAS Number: 6506-37-2

Unique Ingredient Identifier: 469ULX0H4G

Background: Nimorazole has been used in trials studying the treatment of Hypoxia, Radiotherapy, Hypoxic Modification, Gene Profile, Gene Signature, and Head and Neck Squamous Cell Carcinoma, among others.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

DAHANCA 30: A Randomized Non-inferiority Trial of Hypoxia-profile Guided Hypoxic Modification of Radiotherapy of HNSCC.

Phase 3

Conditions: Gene Profile, Gene Signature
Radiotherapy
Hypoxic Modification
Hypoxia
Head and Neck Squamous Cell Carcinoma

Interventions: Drug: Nimorazole

First Posted Date: 2016-01-22

Last Posted Date: 2021-04-13

Lead Sponsor: Danish Head and Neck Cancer Group

Target Recruit Count: 1252

Registration Number: NCT02661152

Locations: 🇩🇰
Department of Experimental Clinical Oncology, Aarhus University Hospital, Aarhus, Denmark

NIMRAD (A Randomised Placebo-controlled Trial of Synchronous NIMorazole Versus RADiotherapy Alone in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Not Suitable for Synchronous Chemotherapy or Cetuximab)

Phase 3

Completed

Conditions: Head and Neck Squamous Cell Carcinoma

Interventions: Drug: Nimorazole
Radiation: Radiotherapy

First Posted Date: 2013-09-25

Last Posted Date: 2021-10-19

Lead Sponsor: The Christie NHS Foundation Trust

Target Recruit Count: 338

Registration Number: NCT01950689

Locations: 🇬🇧
Belfast City Hospital, Belfast, United Kingdom
🇬🇧
Weston Park Hospital, Sheffield, United Kingdom
🇬🇧
Cheltenham General Hospital, Cheltenham, Gloucestershire, United Kingdom

and more 18 locations

AF CRT +/- Nimorazole in HNSCC

Phase 3

Conditions: Locally Advanced Head and Neck HPV Negative Squamous Cell Cancers

Interventions: Drug: Cisplatin
Radiation: Radiotherapy
Drug: Placebo
Drug: Nimorazole

First Posted Date: 2013-06-19

Last Posted Date: 2022-05-10

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 640

Registration Number: NCT01880359

Locations: 🇳🇱
Radboud University Medical Center Nijmegen, Nijmegen, Netherlands
🇦🇺
Princess Alexandra Hospital - University Of Queensland, Brisbane, Australia
🇩🇪
Charite - Universitaetsmedizin Berlin - Campus Virchow-Klinikum, Berlin, Germany

and more 16 locations

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy